Equities research analysts predict that Selecta Biosciences Inc (NASDAQ:SELB) will post ($0.61) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Selecta Biosciences’ earnings. Selecta Biosciences posted earnings per share of ($0.88) in the same quarter last year, which would suggest a positive year-over-year growth rate of 30.7%. The company is expected to report its next earnings report on Thursday, March 21st.
According to Zacks, analysts expect that Selecta Biosciences will report full year earnings of ($2.85) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($2.73) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for Selecta Biosciences.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08.
Shares of SELB stock traded down $0.08 during trading on Tuesday, reaching $2.04. 152,611 shares of the company’s stock were exchanged, compared to its average volume of 344,652. Selecta Biosciences has a twelve month low of $1.97 and a twelve month high of $16.55.
A number of hedge funds and other institutional investors have recently modified their holdings of SELB. Renaissance Technologies LLC acquired a new position in Selecta Biosciences in the 3rd quarter valued at $196,000. Rhumbline Advisers grew its holdings in shares of Selecta Biosciences by 43.7% during the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after purchasing an additional 5,103 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in shares of Selecta Biosciences during the 3rd quarter worth $225,000. Virtu Financial LLC acquired a new stake in shares of Selecta Biosciences during the 3rd quarter worth $363,000. Finally, Marshall Wace LLP acquired a new stake in shares of Selecta Biosciences during the 3rd quarter worth $396,000. 51.04% of the stock is currently owned by hedge funds and other institutional investors.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Further Reading: When is a capital gain realized?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.